secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2026-06-01T12:00:26+00:00
Accession:  0001104659-26-068591
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA clears IND for VY1706, Voyager's tau-silencing gene therapy for Alzheimer's
-------------------------------------------------------------------------------

- VY1706 targets intra- and extracellular tau; IND cleared by FDA on June 1, 2026.
- Phase 1 open-label, dose-escalation trial expected to begin dosing in H2 2026.
- Trial to enroll up to 18 early AD patients across 3 cohorts; highest dose 5 x 10^13 vg/kg.
- Primary endpoint: safety/tolerability; secondary endpoints: CSF tau biomarkers and tau PET imaging.
- Company plans to initiate multi-site study; VY1706 administered as one-time IV dose.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000110465926068591/0001104659-26-068591-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000110465926068591/tm2616041d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-068591

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer